Phoenix Tissue Repair, Inc. Email Format

BiotechnologyMassachusetts, United States2-10 Employees

Phoenix Tissue Repair, Inc. is a biotechnology research company focused on developing therapies for recessive dystrophic epidermolysis bullosa (RDEB), a rare skin condition caused by a deficiency in human collagen type VII. Its work centers on PTR-01, an intravenously administered protein replacement approach, with a history of advancing through early-stage clinical studies and extending a Phase 2 trial to continue treatment and monitoring outcomes. The company operates in the biotechnology research sector and is based in Boston, Massachusetts. With a small team, Phoenix Tissue Repair positions itself in the niche of regenerative medicine targeting genetic skin diseases, aiming to address a pathophysiology that leaves patients prone to skin fragility and blistering. A recent development noted is the launch of a Phase 2 extension study, enabling ongoing assessment of PTR-01 in participants.

Sign up for free to view info

Company overview Employee directory